New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting

Dateline City: KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate  Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558 An Phan, 908-255-6325 or Investors: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Related Links:

Authors: Dousset L, Boniface K, Seneschal J Abstract Antibody-based therapeutics targeting programmed cell death 1 (PD-1) have shown strong efficacy in the treatment of metastatic cancers as melanoma. However, restoring the immune function with these therapies to target cancer cells leads to immune side effects including immune cutaneous events. Vitiligo-like lesions in patients receiving anti-PD-1 is one of the most common skin adverse event reported and the incidence seems to be higher than in patients receiving other immune-checkpoints therapies. Initially described in patients with metastatic melanoma, vitiligo...
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
ConclusionSerious AEs occurred in 80  + adults at the same rate as observed in our younger patients and as previously reported in younger populations. Ipilimumab can be an option in elderly patients, as patients may benefit from therapy and safety seems to be manageable.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Worse survival in states with more physicians; higher death rates in states with lower incidence
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Journal, Source Type: news
Conditions:   Metastatic Solid Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Non-small Cell Lung Cancer (NSCLC);   Melanoma;   Head and Neck Squamous Cell Carcinoma (HNSCC);   Gastric Adenocarcinoma;   Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Esophageal  Adenocarcinoma Intervention:   Drug: INBRX-105 Sponsor:   Inhibrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 18 January 2019Source: Current Therapeutic ResearchAuthor(s): Klaus Rose, Philip D Walson
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
Authors: Romano E, Rufo N, Korf H, Mathieu C, Garg AD, Agostinis P Abstract [This corrects the article DOI: 10.18632/oncotarget.24815.]. PMID: 30651937 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Swenson S, Silva-Hirschberg C, Wang W, Singh A, Hofman FM, Chen KL, Schönthal AH, Chen TC Abstract Despite new treatments introduced over the past several years, metastatic melanoma remains difficult to cure. Although melanoma in situ (MIS) has better prognosis, it relies heavily on thorough surgical excision, where ill-defined margins can pose a challenge to successful removal, potentially leading to invasive melanoma. As well, MIS in the head and neck area can create serious aesthetic concerns with regard to the surgical defect and substantial scar formation. Toward improved treatment of localized m...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas. Oncotarget. 2018 Dec 11;9(97):36945-36965 Authors: Figarola JL, Singhal J, Singhal S, Kusari J, Riggs A Abstract BRAF mutations are detected in>50% of all melanomas. These mutations impair the LKB1-AMPK signaling, an important metabolic pathway associated with cell growth, proliferation and survival. Melanoma patients with BRAF mutations are usually treated with BRAF inhibitors such as vemurafenib, but responses are short-lived as...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Gérard C, Hubeau C, Carnet O, Bellefroid M, Sounni NE, Blacher S, Bendavid G, Moser M, Fässler R, Noel A, Cataldo D, Rocks N Abstract Previous studies have linked cancer cell-associated ADAM28 expression with tumor progression and metastatic dissemination. However, the role of host-derived ADAM28 in cancer dissemination processes remains unclear. Genetically engineered-mice fully deficient for ADAM28 unexpectedly display increased lung colonization by pulmonary, melanoma or breast tumor cells. In experimental tumor cell dissemination models, host ADAM28 deficiency is further associated with a d...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Dikshit A, Zhang JY PMID: 30647835 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Melanoma | Merck | Pharmaceuticals | Skin Cancer | Yervoy